Lineage Cell Therapeutics, Inc. (LCTX) P/E Ratio History
Deep ValueTrading at -4.3x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2016–2019
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Lineage Cell Therapeutics, Inc. (LCTX) trades at a price-to-earnings ratio of -4.3x, with a stock price of $1.21 and trailing twelve-month earnings per share of $-0.25.
The current P/E is 159% below its 5-year average of 7.3x. Over the past five years, LCTX's P/E has ranged from a low of 2.9x to a high of 17.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, LCTX trades at a 120% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, LCTX trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LCTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
LCTX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
LCTX Historical P/E Data (2016–2019)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2019 Q2 | Jun 30 2019 | $1.10 | $0.28 | 3.9x | -46% |
| FY2019 Q1 | Mar 31 2019 | $1.31 | $0.45 | 2.9x | -60% |
| FY2017 Q3 | Sep 30 2017 | $2.84 | $0.42 | 6.8x | -8% |
| FY2017 Q2 | Jun 30 2017 | $3.15 | $0.60 | 5.2x | -29% |
| FY2017 Q1 | Mar 31 2017 | $3.45 | $0.97 | 3.6x | -52% |
| FY2016 Q4 | Dec 31 2016 | $3.61 | $0.32 | 11.3x | +53% |
| FY2016 Q3 | Sep 30 2016 | $3.90 | $0.22 | 17.7x | +141% |
Average P/E for displayed period: 7.3x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LCTX — Frequently Asked Questions
Quick answers to the most common questions about buying LCTX stock.
What is LCTX's P/E ratio?
Lineage Cell Therapeutics, Inc. (LCTX) trailing twelve-month P/E ratio is -4.3x, based on TTM diluted EPS of $-0.25. The 5-year average P/E is 7.3x and the historical range spans 2.9x to 17.7x.
Is LCTX stock overvalued or undervalued?
LCTX trades at -4.3x P/E, below its 5-year average of 7.3x. At the 0th percentile of its historical range (2.9x–17.7x), the stock is priced at a discount to its own history.
Is LCTX stock expensive?
No, LCTX is not expensive on a historical basis. The current P/E of -4.3x is below the 5-year average of 7.3x and sits at the 0th percentile of its valuation range.
What is LCTX's historical P/E range?
Over the past 5 years, LCTX's P/E ratio has ranged from 2.9x to 17.7x, with a median of 5.2x and an average of 7.3x. The current P/E of -4.3x places the stock at the 0th percentile of this range. Full historical data spans 2016–2019.
How does LCTX's P/E compare to the S&P 500?
LCTX trades at -4.3x P/E versus the S&P 500 median of 24.4x. The 118% discount to the market suggests lower growth expectations or perceived higher risk.
How does LCTX's valuation compare to Healthcare peers?
Lineage Cell Therapeutics, Inc. P/E of -4.3x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is LCTX's PEG ratio?
LCTX PEG ratio is N/A, based on a P/E of -4.3x and EPS growth of -201.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is LCTX's earnings yield?
LCTX earnings yield is N/A, the inverse of its -4.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.